This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Modrak, D. E. Articles by Gold, D. V. Search for Related Content PubMed PubMed Citation Articles by Modrak, D. E. Articles by Gold, D. V.

Synergistic Interaction between Sphingomyelin and Gemcitabine Potentiates Ceramide-Mediated Apoptosis in Pancreatic Cancer

Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, New Jersey

We have examined the mechanism by which sphingomyelin (SM) enhances chemotherapy in human pancreatic cancer cells, focusing on the correlation between ceramide metabolism and apoptosis. Dose response curves for gemcitabine in the absence or presence of 0.2 mg/mL SM provided IC₅₀ values of 78.3 ± 13.7 and 13.0 ± 3.0 nmol/L, respectively. The cytotoxic effect of the combined treatment was synergistic (combination index = 0.36). Using annexin-V staining, the percentage of apoptotic cells was 3.6 ± 2.6% for the untreated cells, 6.5 ± 3.8% for the 0.2 mg/mL SM-treated cells, and 19.9 ± 12.9% for the 100 nmol/L gemcitabine-treated cells, but increased significantly to 42.1 ± 12.7% with the combined treatment (P < 0.001, compared with gemcitabine-treated group). The percentage of cells losing mitochondrial membrane potential followed a similar trend. The ceramide content of untreated and gemcitabine-treated cells was not significantly different (0.46 ± 0.29 and 0.59 ± 0.34 pmol ceramide/nmole PO₄). However, when 0.2 mg/mL SM was added, ceramide levels were 1.09 ± 0.42 and 1.58 ± 0.55 pmol ceramide/nmol PO₄, for the SM alone and SM with gemcitabine-treated cells, respectively (P = 0.038). Acidic SMase was activated by exposure to gemcitabine but not SM, whereas the activities of neutral SMase and glycosylceramide synthase did not change with either gemcitabine or SM. The data are consistent with gemcitabine-induced activation of acidic SMase and indicate that the addition of SM can yield increased production of ceramide, mitochondrial depolarization, apoptosis, and cell death. Because SM by itself is relatively nontoxic, addition of this lipid to agents that induce apoptosis may prove useful to enhance apoptosis and increase cytotoxicity in cancer cells.

This article has been cited by other articles:

				D. E. Modrak, E. Leon, D. M. Goldenberg, and D. V. Gold Ceramide Regulates Gemcitabine-Induced Senescence and Apoptosis in Human Pancreatic Cancer Cell Lines Mol. Cancer Res., June 1, 2009; 7(6): 890 - 896. [Abstract] [Full Text] [PDF]

				T. Moriyama, K. Ohuchida, K. Mizumoto, J. Yu, N. Sato, T. Nabae, S. Takahata, H. Toma, E. Nagai, and M. Tanaka MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance Mol. Cancer Ther., May 1, 2009; 8(5): 1067 - 1074. [Abstract] [Full Text] [PDF]

				J. Guillermet-Guibert, L. Davenne, D. Pchejetski, N. Saint-Laurent, L. Brizuela, C. Guilbeau-Frugier, M.-B. Delisle, O. Cuvillier, C. Susini, and C. Bousquet Targeting the sphingolipid metabolism to defeat pancreatic cancer cell resistance to the chemotherapeutic gemcitabine drug Mol. Cancer Ther., April 1, 2009; 8(4): 809 - 820. [Abstract] [Full Text] [PDF]

				S. Michienzi, B. Bucci, C. Verga Falzacappa, V. Patriarca, A. Stigliano, L. Panacchia, E. Brunetti, V. Toscano, and S. Misiti 3,3',5-Triiodo-L-thyronine inhibits ductal pancreatic adenocarcinoma proliferation improving the cytotoxic effect of chemotherapy J. Endocrinol., May 1, 2007; 193(2): 209 - 223. [Abstract] [Full Text] [PDF]

				C. E. Senkal, S. Ponnusamy, M. J. Rossi, J. Bialewski, D. Sinha, J. C. Jiang, S. M. Jazwinski, Y. A. Hannun, and B. Ogretmen Role of human longevity assurance gene 1 and C18-ceramide in chemotherapy-induced cell death in human head and neck squamous cell carcinomas Mol. Cancer Ther., February 1, 2007; 6(2): 712 - 722. [Abstract] [Full Text] [PDF]

				D. E. Modrak, D. V. Gold, and D. M. Goldenberg Sphingolipid targets in cancer therapy. Mol. Cancer Ther., February 1, 2006; 5(2): 200 - 208. [Abstract] [Full Text] [PDF]